Skip to content

The clinical study on the effects of bone metabolism in diabetic nephropathy treated by alendronate

The clinical study on the effects of bone metabolism in diabetic nephropathy treated by alendronate

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-11001837
Enrollment
Unknown
Registered
2011-12-10
Start date
2011-12-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy, bone metabolism

Interventions

Level 1 of uring protein:Alendronate+Calcium Carbonate and Vitamin D3 Table
Level 2 of uring protein:Alendronate+Calcium Carbonate and Vitamin D3 Table
Level 3 of uring protein:Alendronate+Calcium Carbonate and Vitamin D3 Table

Sponsors

Department of Endocrine, Zhujiang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 years and older; 2. Diabetes mellitus (any type):Diagnosis is based on the 1999 WHO criteria for diabetes mellitus; 3. A T score less than -2 in the lumbar spine, femoral neck, or total hip in BMD, which was applied by dual-energy x-ray absorptiometry; 4. Able and willing to give informed consent.

Exclusion criteria

Exclusion criteria: 1. A history of reflux esophagitis, active gastric or duodenal ulcer, gastrectomy,achalasia, or any abnormalities in the esophagus which would lead to lag in esophageal emptying; 2. A history of some illness affecting bone metabolism: primary hyperparathyroidism, hyperthyroidism, multiple myeloma,Paget's disease of bone, rheumatoid arthritis, osteogenesis imperfecta,and a recent fracture (within the previous 3 months); 3. Pregnancy and breast feeding women, or patients who are planning to become pregnant; 4. GFR <35 mL/min; 5. incapability to sit for at least 30 minutes; 6. Pre-planned dental surgery.

Design outcomes

Primary

MeasureTime frame
BMD;

Secondary

MeasureTime frame
PINP;CTx;

Countries

China

Contacts

Public ContactCai Dehong
cai_de_hong@126.com+86 13808843648

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026